Regenerex Pharma (RGPX) Operating Leases (2023 - 2025)
Regenerex Pharma (RGPX) reported Operating Leases of $392884.0 for Q3 2025, down 27.19% year-over-year from $539594.0 in Q3 2024, and down 14.38% on a QoQ basis from $458858.0 in Q2 2025.
Regenerex Pharma (RGPX) has 3 years of Operating Leases data on file, last reported at $392884.0 in Q3 2025.
- Quarterly Operating Leases fell 27.19% year-over-year to $392884.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $392884.0 (down 27.19% YoY) and the FY2025 annual result came in at $495894.0, down 27.27% from the prior year.
- Operating Leases slipped to $392884.0 in Q3 2025 per RGPX's latest filing, from $458858.0 in the prior quarter.
- Across five years, Operating Leases topped out at $803845.0 in Q2 2023 and bottomed at $392884.0 in Q3 2025.
- The 3-year median for Operating Leases is $584746.0 (2024), against an average of $603003.3.
- Peak annual rise in Operating Leases reached 21.76% in 2024, while the deepest fall reached 29.39% in 2024.
- Tracing RGPX's Operating Leases over 3 years: stood at $723497.0 in 2023, then slipped by 25.29% to $540528.0 in 2024, then slipped by 27.31% to $392884.0 in 2025.
- Per Business Quant, the three latest RGPX Operating Leases figures stand at $392884.0 (Q3 2025), $458858.0 (Q2 2025), and $495894.0 (Q1 2025).
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 392,884.00 |
| Jun 30, 2025 | 458,858.00 |
| Mar 31, 2025 | 495,894.00 |
| Dec 31, 2024 | 540,528.00 |
| Sep 30, 2024 | 539,594.00 |
| Jun 30, 2024 | 628,964.00 |
| Mar 31, 2024 | 681,798.00 |
| Dec 31, 2023 | 723,497.00 |
| Sep 30, 2023 | 764,171.00 |
| Jun 30, 2023 | 803,845.00 |